Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of his presentation at this year's Texas MPN Workshop, which focused on approaches to managing cytopenias in myelofibrosis (MF). Dr Bose first comments on the options currently available in this space, and then goes on to highlight novel agents and strategies being explored, including dosing strategies with ruxolitinib and the impact of the recent approval of pacritinib. To conclude, Dr Bose highlights the promise of momelotinib and other agents being evaluated, and how these may move the field forward. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

свернуть